Routine pelvic lymphadenectomy in apparently early stage endometrial cancer

L. D. Zuurendonk, R. A. Smit, B. W.J. Mol, H. W.H. Feijen, J. de Graaff, D. Sykora, K. A.J. de Winter, A. vd Wurff, M. P.M.L. Snijders, R. F.P.M. Kruitwagen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Aims: Controversial issues with respect to the treatment of patients with endometrial cancer include indications for lymphadenectomy and adjuvant radiotherapy. Patient and methods: Between 1998 and 2004 all women with endometrial cancer stage I were included (n=335). They all underwent total abdominal hysterectomy and bilateral salpingo-oöphorectomy. Two hundred and thirty-seven women also had a pelvic lymphadenectomy. When pelvic lymphadenectomy was performed, radiotherapy was administered only to patients with lymph-node metastases. Otherwise, adjuvant radiotherapy was based on the presence of risk factors. Results: Eleven patients had lymph-node metastases. The overall absolute and relative survival-estimate at 5 years was 85.0 and 93.7%, respectively. Loco-regional recurrence was 8.5%. In the group with pelvic lymphadenectomy and negative lymph nodes these rates were 88.2, 93.9 and 5.6%, respectively. In 58 patients without any of the risk factors tumour grade III, deep myometrial invasion, or age ≥60 years, no lymph-node metastases were found. Conclusion: In patients with endometrial cancer FIGO stage I without risk-factors, a phenomenon which occurs in about 25% of patients with clinical stage I endometrial cancer, a lymphadenectomy can be omitted. In other patients, the debate regarding the optimal treatment will remain.

Original languageEnglish
Pages (from-to)450-454
Number of pages5
JournalEuropean Journal of Surgical Oncology
Issue number4
Publication statusPublished - 1 May 2006


  • Endometrial carcinoma
  • Lymph node excision
  • Lymphatic metastases
  • Survival rate


Dive into the research topics of 'Routine pelvic lymphadenectomy in apparently early stage endometrial cancer'. Together they form a unique fingerprint.

Cite this